Radiopharm Theranostics Limited American Depositary Shares (RADX)

• Market cap: $52.5M
• 1 day: 3.85%
• 5 days: 22.28%
• 1 month: 38.04%
• 3 months: 31.84%
• 6 months: 8.87%
• Year to date: 45.47%
• 1 year: -61.8%
• 5 years: -61.8%
• 10 years: -61.8%
• Sector: Healthcare
• Industry: Biotechnology

About: Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

67% more funds holding

Funds holding: 3 [Q1] → 5 (+2) [Q2]

4.29% more ownership

Funds ownership: 0.01% [Q1] → 4.31% (+4.29%) [Q2]

4% less capital invested

Capital invested by funds: $1.65M [Q1] → $1.58M (-$72.5K) [Q2]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $18
• Avg. target: $18
• High target: $18

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Brookline Capital Kemp Dolliver

$18

Buy Initiated

21 Jul 2025